Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552382 | 0.86 | MMP1 (0.48) | MAPTCHRNA7SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5558599 | 0.76 | MMP9 (0.57) | NPC1 | |
| SCHEMBL5552855 | 0.75 | ERAP2 (0.59) | TP53 | |
| SCHEMBL5556442 | 0.73 | TSHR (0.48) | SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL5552391 | 0.73 | HDAC1 (0.48) | MAPTSMN1; SMN2KDM4EALDH1A1NPC1 | |
| SCHEMBL5552466 | 0.71 | ATM (0.49) | ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL5558596 | 0.71 | CTSD (0.49) | MAPTPOLBALDH1A1KMT2AGAA | |
| SCHEMBL5557781 | 0.68 | ANPEP (0.57) | MAPTSMN1; SMN2KDM4ELMNAALDH1A1 | |
| SCHEMBL5556818 | 0.68 | MMP8 (0.56) | — | |
| SCHEMBL12804151 | 0.67 | POLB (0.51) | MAPTPOLBCHRNA7SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | MAPT 4430/4885HCRTR1 4340/4885POLB 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.